Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00604825




Registration number
NCT00604825
Ethics application status
Date submitted
17/01/2008
Date registered
30/01/2008
Date last updated
3/10/2017

Titles & IDs
Public title
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Scientific title
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Secondary ID [1] 0 0
105106
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Menopausal and Female Climacteric States 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Placebo comparator: Placebo - Placebo

Active comparator: GSK232802 - GSK232802

Experimental: PREMARIN - PREMARIN
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE
Timepoint [1] 0 0
Up to 21 weeks
Primary outcome [2] 0 0
Change From Baseline in Vital Signs of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 12
Timepoint [2] 0 0
Baseline (Week 0) and Week 12
Primary outcome [3] 0 0
Change From Baseline in Vital Sign of Heart Rate at Week 12
Timepoint [3] 0 0
Baseline (Week 0) and Week 12
Primary outcome [4] 0 0
Change From Baseline in Thyroid Stimulating Hormone (TSH) at Week 12
Timepoint [4] 0 0
Baseline (Week 0) and Week 12
Primary outcome [5] 0 0
Change From Baseline in Thyroxine (T4) and Insulin at Week 12
Timepoint [5] 0 0
Baseline (Week 0) and Week 12
Primary outcome [6] 0 0
Change From Baseline in Fasting Lipid Profile at Week 12
Timepoint [6] 0 0
Baseline (Week 0) and Week 12
Primary outcome [7] 0 0
Change From Baseline in Bi-layer Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS) or Saline Infusion Sonohysterography (SIS)
Timepoint [7] 0 0
Baseline (Week 0) to Week 12
Primary outcome [8] 0 0
Endometrial Biopsy Pathology
Timepoint [8] 0 0
Baseline (Week 0) to Week 12
Primary outcome [9] 0 0
Occurrence of Withdrawal Bleeding-duration of Spotting/Bleeding
Timepoint [9] 0 0
Up to Follow-up (Day 112)
Primary outcome [10] 0 0
Occurrence of Withdrawal Bleeding-number of Days of Spotting, Number of Days of Bleeding, Number of Days of Spotting/Bleeding Combined
Timepoint [10] 0 0
Up to Follow-up (Day 112)
Primary outcome [11] 0 0
Mean Change in Frequency of Vasomotor Symptoms (VMS) From Baseline at Week 12
Timepoint [11] 0 0
Baseline (Week 0) and Week 12
Primary outcome [12] 0 0
Mean Change in Severity of VMS From Baseline at Week 12
Timepoint [12] 0 0
Baseline (Week 0) and Week 12
Primary outcome [13] 0 0
Change From Baseline in Thrombotic Marker- Fibrinogen at Week 12
Timepoint [13] 0 0
Baseline (Week 0) and Week 12
Primary outcome [14] 0 0
Change From Baseline in Thrombotic Marker- Tissue Plasminogen Activator (tPA) Antigen at Week 12
Timepoint [14] 0 0
Baseline (Week 0) and Week 12
Primary outcome [15] 0 0
Change From Baseline and Week 12 in Inflammatory Marker- High Sensitivity C-reactive Protein (Hs-CRP) at Week 12
Timepoint [15] 0 0
Baseline (Week 0) and Week 12
Primary outcome [16] 0 0
Change From Baseline and Week 12 in Inflammatory Marker- Endothelin-1 at Week 12
Timepoint [16] 0 0
Baseline (Week 0) and Week 12
Primary outcome [17] 0 0
Change From Baseline and Week 12 in Hematology Parameter- Hematocrit at Week 12
Timepoint [17] 0 0
Baseline (Week 0) and Week 12
Primary outcome [18] 0 0
Change From Baseline in Hematology Parameter- Mean Corpuscle Hemoglobin (MCH) at Week 12
Timepoint [18] 0 0
Baseline (Week 0) and Week 12
Primary outcome [19] 0 0
Change From Baseline in Hematology Parameter- Mean Corpuscle Volume (MCV) at Week 12
Timepoint [19] 0 0
Baseline (Week 0) and Week 12
Primary outcome [20] 0 0
Change From Baseline in Hematology Parameter- Red Blood Cell (RBC) Count at Week 12
Timepoint [20] 0 0
Baseline (Week 0) and Week 12
Primary outcome [21] 0 0
Change From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at Week 12
Timepoint [21] 0 0
Baseline (Week 0) and Week 12
Primary outcome [22] 0 0
Change From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Segmented Neutrophils, Total Neutrophils and White Blood Cell (WBC) Count at Week 12
Timepoint [22] 0 0
Baseline (Week 0) and Week 12
Primary outcome [23] 0 0
Change From Baseline in Clinical Chemistry Parameters- Albumin and Total Protein at Week 12
Timepoint [23] 0 0
Baseline (Week 0) and Week 12
Primary outcome [24] 0 0
Change From Baseline in Clinical Chemistry Parameters- Creatinine, Direct Bilirubin, Total Bilirubin and Uric Acid at Week 12
Timepoint [24] 0 0
Baseline (Week 0) and Week 12
Primary outcome [25] 0 0
Change From Baseline in Clinical Chemistry Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) at Week 12
Timepoint [25] 0 0
Baseline (Week 0) and Week 12
Primary outcome [26] 0 0
Change From Baseline in Clinical Chemistry Parameters- Calcium, Carbon Dioxide (C02) Content, Chloride, Phosphorous, Inorganic, Potassium, Sodium and Urea at Week 12
Timepoint [26] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [1] 0 0
Mean Change in Frequency of VMS From Baseline to Weeks 4 and 8
Timepoint [1] 0 0
Baseline (Week 0) to Week 8
Secondary outcome [2] 0 0
Mean Change in Severity of VMS From Baseline to Weeks 4 and 8
Timepoint [2] 0 0
Baseline (Week 0) to Week 8
Secondary outcome [3] 0 0
Number of Participants With VMS Percent Change From Baseline Responders With a Reduction in Frequency at Week 12 of at Least 50%, at Least 75%, and 100%
Timepoint [3] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [4] 0 0
Number of Participants With VMS Percent Change From Baseline Responders With a Reduction in Severity at Week 12 of at Least 50%, at Least 75%, and 100%
Timepoint [4] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [5] 0 0
Change in Menopause Quality of Life (MENQoL) Score From Baseline to Visits 6 (Week 4) and Visit 8 (Week 12)
Timepoint [5] 0 0
Baseline (Week 0) to Week 12
Secondary outcome [6] 0 0
Change in Medical Outcomes Study (MOS) Sleep Score From Baseline to Visits 6 (Week 4) and Visit 8 (Week 12)
Timepoint [6] 0 0
Baseline (Week 0) to Week 12
Secondary outcome [7] 0 0
Changes in Vulvar Vaginal Atrophy (VVA) Symptom Score From Baseline to Visit 8 (Week 12)
Timepoint [7] 0 0
Baseline (Week 0) to Visit 8 (Week 12)
Secondary outcome [8] 0 0
Change in Brief Fatigue Inventory (BFI) Score From Visit 2 to Visit 7
Timepoint [8] 0 0
Visit 2 (Day -21) to Visit 7 (Week 8)
Secondary outcome [9] 0 0
Change in the Centers for Epidemiologic Studies in Depression (CES-D) Score From Visit 2 to Visit 7
Timepoint [9] 0 0
Visit 2 (Day -21) to Visit 7 (Week 8)
Secondary outcome [10] 0 0
Change in Work Productivity and Activity Impairment (WPAI) Score From Visit 2 to Visit 7
Timepoint [10] 0 0
Visit 2 (Day -21) to Visit 7 (Week 8)
Secondary outcome [11] 0 0
Change From Visit 2 to Visit 8 in Vaginal pH
Timepoint [11] 0 0
Visit 2 (Day -21) to Visit 8 (Week 12)
Secondary outcome [12] 0 0
Change From Visit 2 to Visit 8 in Percentage of Superficial Cells to Determine the Vaginal Maturation Index (VMI)
Timepoint [12] 0 0
Visit 2 (Day -21) to Visit 8 (Week 12)
Secondary outcome [13] 0 0
Change From Baseline in Glucose at Week 12
Timepoint [13] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [14] 0 0
Change From Baseline at Week 12 in Serum Hormone Levels- Estradiol
Timepoint [14] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [15] 0 0
Change From Baseline at Week 12 in Serum Hormone Levels- Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)
Timepoint [15] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [16] 0 0
Change From Baseline at Week 12 in Serum Hormone Levels- Testosterone
Timepoint [16] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [17] 0 0
Change From Baseline at Week 12 in Waist Circumference
Timepoint [17] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [18] 0 0
Change From Baseline at Week 12 in Hip Circumference
Timepoint [18] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [19] 0 0
Change From Baseline at Week 12 in Weight
Timepoint [19] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [20] 0 0
Change From Baseline at Week 12 in Body Mass Index (BMI)
Timepoint [20] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [21] 0 0
Change From Baseline at Week 12 in Abdomen Body Circumference, Abdomen Saggital Diameter and Thigh Circumference
Timepoint [21] 0 0
Baseline (Week 0) and Week 12
Secondary outcome [22] 0 0
Change From Baseline at Week 12 in Abdomen Visceral Adipose Tissue (AVAT), Abdomen Subcutaneous Adipose Tissue (ASAT), Thigh Subcutaneous Adipose Tissue (TSAT) and Thigh Intermuscular Adipose Tissue (TIAT)
Timepoint [22] 0 0
Baseline (Week 0) and Week 12

Eligibility
Key inclusion criteria
A subject will be eligible for inclusion in this study only if all of the following criteria apply:

* Postmenopausal women aged 40 to 65 years old; postmenopausal defined as:

i.Amenorrheic for at least 12 consecutive months* OR ii.At least 6 weeks post-surgical bilateral oophorectomy† with or without hysterectomy.

*Note: Although duration of amenorrhea is initially determined by subject history at the time of the screening visit (Visit 1), menopausal status must be confirmed by demonstrating levels of follicle stimulating hormone (FSH) >40 mIU/mL (SI: >40 IU/L) and estradiol <35pg/mL (SI: <128pmol/L) at entry. Screening reports provided by the Central Laboratory must be carefully reviewed to determine menopause eligibility prior to conducting Visit 2 assessments. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or estradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility should be discussed with the study medical monitor.

†For women who are surgically menopausal, a copy of the pathology report or a statement on letterhead from the subject's physician documenting both ovaries have been removed or biochemical evidence of post-menopausal status as noted above is required prior to conducting Visit 2 assessments.
* A minimum average frequency of seven daily moderate to extremely severe hot flashes or episodes of night sweats sufficient to cause the patient to seek treatment (these episodes must be documented during the baseline period and the subject must have recorded frequency and severity of symptoms for a minimum of eight days in order to be eligible for randomization). This average frequency will be calculated by summing the number of moderate, severe, and extremely severe VMS events during the baseline period and dividing by the total number of non-missing days during this period, with details related to the definition of non-missing days described in Section 6.3.1.
* BMI within the range 19 to 35 kg/m2, inclusive.
* Subject has provided signed and dated written informed consent before admission to the study.
* Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.
Minimum age
40 Years
Maximum age
65 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:

* Investigator considers subject unfit for the study as a result of medical history, physical examination, or screening tests.
* Use of prescription or non-prescription drugs including:

i.Hormone therapy (estrogen or estrogen/progestin combination or related products) within the following time period prior to conduct of Visit 1 assessments:
* 4 weeks for prior vaginal hormonal products (rings, creams, gels) or transdermal estrogen or estrogen/progestin products.
* 4 weeks for oral estradiol (e.g., micronized estradiol) or SERM products (e.g., raloxifene).
* 8 weeks for prior oral conjugated (equine or synthetic) estrogen or estrogen/progestin products or for prior intrauterine progestin therapy.
* 3 months for prior progestin implants or injectable estrogen.
* 6 months for prior estrogen pellet therapy or injectable progestin. ii.Use of putative therapies for VMS relief (e.g., selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], clonidine, gabapentin, tibolone, methyldopa, and the phytoestrogens black cohosh and red clover) within the past 30 days or 5 half-lives (whichever is longer) prior to conduct of Visit 1 assessments (note: half-lives will be provided in the SPM). Use of non-medication treatments for VMS, such as acupuncture and biofeedback, and other complementary or alternative therapies for VMS relief (with the exception of black cohosh and red clover which require a specified washout previously noted) must be discontinued at Visit 1.

iii.Use of weight loss drugs (e.g., phentermine, sibutramine, orlistat, rimonabant) within 3 months of the first dose of investigational product. Other complementary or alternative therapies for weight reduction must be discontinued at Visit 1. See SPM for listing.

iv.Use of pravastatin [Pravachol/Lipostat], rosuvastatin [Crestor], or pitavastatin [Livalo] within the past 30 days or 5 half-lives (whichever is longer) of the first dose of investigational product (note: half-lives will be provided in the SPM. Uses of other statins, for example simvastatin [Zocor], atorvastatin [Lipitor], fluvastatin [Lescol], lovastatin [Mevacor] is allowed).

v.Use of bupropion, orphenadrine [Norflex], cyclophosphamide, efavirenz, ifosfamide, or methadone (because of the potential for GSK232802 to inhibit CYP2B6), or use of paclitaxel, torsemide, amodiaquine, repaglinide, rosiglitazone, or pioglitazone (because of the potential for GSK232802 to inhibit CYP2C8) within the past 30 days or 5 half-lives (whichever is longer) of the first dose of investigational product (note: half-lives will be provided in the SPM).

Please note: Regardless of the reason for prescribing, use of the medications and therapies defined within Exclusion 2 above is prohibited. Concurrent administration of anti-depressants, anti-hypertensives, lipid-lowering therapies, etc. not specifically excluded above is allowed. See SPM for detailed listings and relevant half lives.

- Use of investigational drug within the past 30 days or 5 half-lives (whichever is longer) before the first dose of investigational product.

* Uterine disease or medical condition including:
* Bi-layer endometrial thickness greater than 5mm as determined by TVUS, or for women with a non-informative TVUS, a single layer thickness of greater than 3 mm determined by SIS; presence of fibroids that obscure evaluation of endometrium by TVUS;
* History of uterine cancer; evidence of endometrial hyperplasia or cancer as assessed by a screening endometrial biopsy. (Note: if a subject has insufficient tissue for diagnosis at screening, but bi-layer endometrial thickness by TVUS is =5mm or single wall thickness by SIS is =3mm, she may still be eligible for study entry if she meets the remaining inclusion/exclusion criteria);
* Evidence of an endometrial polyp with hyperplastic or malignant epithelium;
* Unexplained or unusual endometrial bleeding; or uterine surgery (other than hysterectomy*) within the past 6 months; *Note: hysterectomy must have been conducted at least 6 weeks prior to screening Visit 1. See also Inclusion criterion 1.
* Abnormal cervical Pap smear with evidence of cervical dysplasia greater than or equal to low grade squamous intraepithelial lesion (LSIL) or with a diagnosis of atypical squamous cells of undetermined significance (ASCUS) that is HPV High Risk positive, or glandular lesions including but not limited to atypical glandular cells of undetermined significance (AGUS), adenocarcinoma in situ (AIS) or malignancy
* History of breast or ovarian cancer. Any clinically significant findings on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer (note: simple cysts confirmed by ultrasound are allowed).

Note: A screening mammogram is required unless the subject has had a mammogram performed within the last 12 months. If local mammography or medical management guidelines restrict the frequency with which mammograms can be performed, or impose age restrictions on the use of mammography, such that a subject may be unable to undergo the study-required screening mammogram, then these subjects must not be enrolled in the study. See Section 6.2.7.

- Cardiovascular conditions including: i. Systolic blood pressure (BP) outside the range 80 to 150 mmHg, diastolic BP outside the range 50 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm. Subjects with mild to moderate hypertension who are controlled on a stable antihypertension regimen may be enrolled if they meet the inclusion/exclusion criteria.

ii. Symptomatic or asymptomatic arrhythmia of any clinical significance. iii. Any clinically significant abnormality identified on the screening 12-lead ECG. Subjects with QTc prolongation (QTc interval >450msec) will be excluded.

iv. Has a documented history (within the last year) of myocardial infarction, angina, or has undergone coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty (PTCA).

v. History of venous or arterial thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke), history of known coagulopathy or abnormal coagulation factors; increased thrombotic risk as evidenced by positive APC resistance (APCR) evaluated at screening.

- Has a documented history of hepatobiliary disease or hepatic enzyme elevation including any one of the following: i.ALT or direct (conjugated) bilirubin values 1.5-fold higher than the ULN at screening.

ii.Fasting triglycerides >400mg/dL (SI: >4.52mmol/L) at screening. If a subject is receiving a lipid-lowering therapy, then she must be on a stable dose for at least 1 month before screening.

* Has an abnormal thyroid function test assessed by TSH at screening (TSH <0.1uU/mL or >10uU/mL [SI: <0.1mU/L or >10mU/L] ).

Note: If the TSH is mildly out of range at screening (TSH < 15U/mL), the subject may have her dose adjusted (if already on exogenous therapy) or have therapy initiated as deemed appropriate by the subject's physician, followed by a 3-4 week period to allow adequate equilibration. The TSH may then be re-assayed for eligibility purposes after this stabilization period has been completed. The subject should not progress through subsequent V2 assessments until re-assay demonstrates the TSH is within acceptable protocol-defined limits. Subjects with suppressed levels of TSH, <0.1U/mL, may have dose adjustment if free T4 is in normal range, and they are on exogenous thyroxine therapy.

* Has either a previous disease or current medical condition, which as judged by the investigator, may affect the interpretation of efficacy or safety data or which otherwise contraindicates participation in a clinical study with a new chemical entity. These diseases include, but are not limited to, cardiovascular disease, malignancy*, complex ovarian pathology, hepatic disease, renal disease, hematological disease, neurological disease, or endocrine disease. A subject with diabetes may be included if her diabetes is well controlled (i.e., HbA1c level is less than 8% at screening).

*Note: Any history of malignancy within the past 5 years is exclusionary with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Subjects with a prior malignancy who have had no evidence of disease for at least the past 5 years are eligible. Note that this timeframe does not apply to uterine, breast, and ovarian cancers which are defined in Exclusions 4 and 5 above.
* History of alcohol or substance abuse or dependence in the 12 months before screening as determined by the investigator.
* Positive results for hepatitis B surface antigen or hepatitis C antibodies as evaluated at screening Visit 1. Known history of HIV.
* Donation of blood in excess of 500mL within a 56-day period before screening.
* History or presence of allergy to the investigational product or drugs of this class (e.g., raloxifene), or history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/07/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/07/2008
Sample size
Target
Accrual to date
Final
356
Recruitment in Australia
Recruitment state(s)
QLD,SA,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Auchenflower
Recruitment hospital [2] 0 0
GSK Investigational Site - Kippa Ring
Recruitment hospital [3] 0 0
GSK Investigational Site - Dulwich
Recruitment hospital [4] 0 0
GSK Investigational Site - Nedlands
Recruitment hospital [5] 0 0
GSK Investigational Site - Subiaco
Recruitment postcode(s) [1] 0 0
4066 - Auchenflower
Recruitment postcode(s) [2] 0 0
4021 - Kippa Ring
Recruitment postcode(s) [3] 0 0
5065 - Dulwich
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment postcode(s) [5] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Montana
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New Mexico
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Autonoma de Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autónoma de Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Mendoza
Country [27] 0 0
Germany
State/province [27] 0 0
Hessen
Country [28] 0 0
Germany
State/province [28] 0 0
Niedersachsen
Country [29] 0 0
Germany
State/province [29] 0 0
Nordrhein-Westfalen
Country [30] 0 0
Germany
State/province [30] 0 0
Sachsen-Anhalt
Country [31] 0 0
Germany
State/province [31] 0 0
Sachsen
Country [32] 0 0
Germany
State/province [32] 0 0
Thueringen
Country [33] 0 0
Germany
State/province [33] 0 0
Berlin
Country [34] 0 0
Germany
State/province [34] 0 0
Hamburg
Country [35] 0 0
Italy
State/province [35] 0 0
Campania
Country [36] 0 0
Italy
State/province [36] 0 0
Emilia-Romagna
Country [37] 0 0
Italy
State/province [37] 0 0
Toscana
Country [38] 0 0
New Zealand
State/province [38] 0 0
Auckland
Country [39] 0 0
New Zealand
State/province [39] 0 0
Christchurch
Country [40] 0 0
New Zealand
State/province [40] 0 0
Wellington
Country [41] 0 0
Spain
State/province [41] 0 0
Lugo
Country [42] 0 0
Spain
State/province [42] 0 0
Oviedo
Country [43] 0 0
Spain
State/province [43] 0 0
Santiago de Compostela
Country [44] 0 0
Sweden
State/province [44] 0 0
Göteborg
Country [45] 0 0
Sweden
State/province [45] 0 0
Kungsbacka
Country [46] 0 0
Sweden
State/province [46] 0 0
Uddevalla
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Cambridgeshire
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Lancashire
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Middlesex
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Oxfordshire
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Waterloo, Liverpool

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00604825